Highly potent, water soluble benzimidazole antagonist for activated α4β1 integrin

Richard D. Carpenter; Mirela Andrei; Edmond Y Lau; Felice C Lightstone; Ruiwu Liu; Kit Lam; Mark J. Kurth

doi:10.1021/jm070790o

Highly potent, water soluble benzimidazole antagonist for activated α₄β₁ integrin

Richard D. Carpenter, Mirela Andrei, Edmond Y Lau, Felice C Lightstone, Ruiwu Liu, Kit Lam, Mark J. Kurth

Research output: Contribution to journal › Article

27 Scopus citations

Abstract

The cell surface receptor α₄β₁ integrin, activated constitutively in lymphoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A). However, concerns on its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzimidazole moiety, resulting in improved solubility while maintaining picomolar potency [5 (KLCA4); IC₅₀ = 305 pM]. With exceptional solubility, this finding has the potential for improving PK to help diagnose and treat lymphomas.

Original language	English (US)
Pages (from-to)	5863-5867
Number of pages	5
Journal	Journal of Medicinal Chemistry
Volume	50
Issue number	23
DOIs	https://doi.org/10.1021/jm070790o
State	Published - Nov 15 2007

ASJC Scopus subject areas

Organic Chemistry

Access to Document

10.1021/jm070790o

Fingerprint Dive into the research topics of 'Highly potent, water soluble benzimidazole antagonist for activated α<sub>4</sub>β<sub>1</sub> integrin'. Together they form a unique fingerprint.

Cite this

Carpenter, R. D., Andrei, M., Lau, E. Y., Lightstone, F. C., Liu, R., Lam, K., & Kurth, M. J. (2007). Highly potent, water soluble benzimidazole antagonist for activated α₄β₁ integrin. Journal of Medicinal Chemistry, 50(23), 5863-5867. https://doi.org/10.1021/jm070790o

@article{0f32fcbe8f7244d991ea08ee583d9e35,

title = "Highly potent, water soluble benzimidazole antagonist for activated α4β1 integrin",

abstract = "The cell surface receptor α4β1 integrin, activated constitutively in lymphoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A). However, concerns on its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzimidazole moiety, resulting in improved solubility while maintaining picomolar potency [5 (KLCA4); IC50 = 305 pM]. With exceptional solubility, this finding has the potential for improving PK to help diagnose and treat lymphomas.",

author = "Carpenter, {Richard D.} and Mirela Andrei and Lau, {Edmond Y} and Lightstone, {Felice C} and Ruiwu Liu and Kit Lam and Kurth, {Mark J.}",

year = "2007",

month = nov,

day = "15",

doi = "10.1021/jm070790o",

language = "English (US)",

volume = "50",

pages = "5863--5867",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "23",

}

TY - JOUR

T1 - Highly potent, water soluble benzimidazole antagonist for activated α4β1 integrin

AU - Carpenter, Richard D.

AU - Andrei, Mirela

AU - Lau, Edmond Y

AU - Lightstone, Felice C

AU - Liu, Ruiwu

AU - Lam, Kit

AU - Kurth, Mark J.

PY - 2007/11/15

Y1 - 2007/11/15

N2 - The cell surface receptor α4β1 integrin, activated constitutively in lymphoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A). However, concerns on its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzimidazole moiety, resulting in improved solubility while maintaining picomolar potency [5 (KLCA4); IC50 = 305 pM]. With exceptional solubility, this finding has the potential for improving PK to help diagnose and treat lymphomas.

AB - The cell surface receptor α4β1 integrin, activated constitutively in lymphoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A). However, concerns on its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzimidazole moiety, resulting in improved solubility while maintaining picomolar potency [5 (KLCA4); IC50 = 305 pM]. With exceptional solubility, this finding has the potential for improving PK to help diagnose and treat lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=36148929378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148929378&partnerID=8YFLogxK

U2 - 10.1021/jm070790o

DO - 10.1021/jm070790o

M3 - Article

C2 - 17948981

AN - SCOPUS:36148929378

VL - 50

SP - 5863

EP - 5867

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 23

ER -